Aerska
PVT · PVT·Dublin, Ireland·Private·Preclinical
Pioneering systemically delivered RNAi medicines for brain diseases using its antibody-oligonucleotide conjugate platform. Brain shuttle technology crosses the blood-brain barrier for durable gene knockdown in neurons. Co-founded by RNAi pioneer Stuart Milstein (ex-Alnylam); targeting genetic forms of Alzheimer's and Parkinson's disease.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Aerska website | Website | May 5, 2026 | 1 |